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Abstract 
Background: Discovery of the progression-associated genes and pathways in lung adeno-
carcinoma (LAD) has important implications in understanding the molecular mechanism of 
tumor development. However, few studies had been performed to focus on the changes of 
pathways in lung adenocarcinoma development using microarray expression profile. 
Result: We performed a meta-analysis of 4 LAD microarray datasets encompassing 353 
patients to reveal differentially expressed genes (DEGs) between normal lung tissues and LAD 
of different stages. Overall, 1 838 genes were found to be dys-regulated, and the adipogenesis, 
circadian rhythm, and Id pathways were significantly changed. Interestingly, most of the genes 
from the same gene family (such as Interleukin receptor, Matrix metallopeptidase, Histone 
cluster and Minichromosome maintenance complex component families) were found to be 
up-regulated (or down-regulated). Real-time PCR (qRT-PCR) was applied to validate the 
expression of randomly selected 18 DEGs in LAD cell lines. In the pathway analysis among 
stages,  Oxidative  stress,  Glycolysis/Gluconeogenesis  and  Integrin-mediated  cell  adhesion 
pathways, which were involved in cancer cell proliferation and metastasis, were showed to be 
significantly regulated in stages other than IA. 
Conclusion: Genes involved in adipogenesis and Id pathways might play important roles in 
development of LADs. The similar trend of expression of the gene family members suggested 
coordinate regulation in tumor progression.  Three pathways (Oxidative stress, Glycoly-
sis/Gluconeogenesis and Integrin-mediated cell adhesion pathways) significantly regulated in 
stages other than stage IA suggested that genes and pathways conferring invasive character 
might be activated in the preinvasive stage IB, while the Oxidative stress and the Glycoly-
sis/Gluconeogenesis  pathways  might  have  strong  connections  to  cisplatin-based  chemo-
therapy. The insignificantly regulated three pathways in stage IA might be used in early-stage 
detection of LAD. 
Key words: meta-analysis, lung adenocarcinoma, pathway, sample size 
Introduction 
Lung cancer is the most common cause of cancer 
death for both men and women worldwide [1]. Gen-
erally,  the  majority  of  cancer  deaths  are  caused  by 
metastasis rather than by the primary tumor itself [2]. 
The development of an oncogenic state is a complex 
process involving the accumulation of multiple inde-
pendent mutations, which lead to deregulation of cell 
signaling pathways on controlling cell growth and cell Int. J. Biol. Sci. 2011, 7 
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fate [3]. The sequential and rate-limiting steps of me-
tastasis involve lots of gene expression, regulations, 
and interactions [4]. 
Lung  adenocarcinoma  (LAD),  a  histological 
subtype of non–small cell lung cancer (NSCLC), has 
increased incidence over the past several decade years 
from 20% of lung cancer cases to nearly 40%, followed 
with a high mortality [5]. Based on the 2004 World 
Health  Organization  Pathologic  Criteria,  the  LADs 
have  four  major  individual  subtypes  (acinar,  papil-
lary,  bronchioloalveolar  carcinoma,  and  solid  carci-
noma with mucus formation) [6]. The acinar pattern is 
characterized by acini and tubules composed of cu-
boidal  or  columnar  cells  which  may  be  mucin  pro-
ducing  and  resemble  bronchial  gland  or  bronchial 
lining  epithelial  cells.  The  papillary  pattern  shows 
papillae with secondary and tertiary papillary struc-
tures  that  replace  the  underlying  lung  architecture. 
Solid  adenocarcinoma  with  mucin  is  composed  of 
sheets polygonal cells lacking acini, tubules, and pa-
pillae but with mucin. Bronchioloalveolar carcinoma 
(BAC) pattern shows growth of neoplastic cells along 
pre-existing  alveolar  structures  without  evidence  of 
stromal, vascular, or pleural invasion [7]. However, 
most of the cases are histologically heterogeneous and 
consist of more than one subtype. The most frequent 
subtype  was  the  adenocarcinomas  mixed  subtype, 
representing  approximately  80%  of  resected  adeno-
carcinomas [6]. 
The most powerful method for NSCLC patients 
prognosis  and  treatment  guiding  is  the  tu-
mor-node-metastasis (TNM) staging system [8]. Based 
on the tumor size (T), local invasion, and presence of 
nodal  (N)  and  distant  metastases  (M),  patients  are 
categorized  into  seven  stages  (IA,  IB,  IIA,  IIB,  IIIA, 
IIIB and IV) [9]. Early stage detection of NSCLC helps 
to  choose  a  proper  treatment  for  patients.  Usually, 
surgical  resection  is  the  first  option  for  early  stage 
subjects, and is considered curative in patients with 
stage  I  lung  cancer  [10].  Recently,  multiple  clinical 
trials have demonstrated that adjuvant chemotherapy 
significantly improved the survival of the patients in 
stage IB-IIIA[11]. The Lung Adjuvant Cisplatin Eval-
uation  (LACE),  which  was  based  on  a  pooled  me-
ta-analysis  of  five  largest  randomized  trials,  has 
demonstrated  that  cisplatin-based  adjuvant  chemo-
therapy  improved  survival  in  patients  with  com-
pletely resected NSCLC especially in stages II and III, 
but may have no benefit for patients with stage IA and 
only a marginal benefit for patients with stage IB [12]. 
However,  the  Japan  Lung  Cancer  Research  Group 
conducted adjuvant trials with uracil-tegafur, show-
ing a survival benefit with adjuvant chemotherapy in 
stage IB LADs [13]. These results suggested that mo-
lecular  mechanisms  occurring  in  stage  IB  might  be 
different from Stage IA. 
Multiple studies have demonstrated the ability 
of  signature  genes,  which  derived  from  microarray 
expression profiles, to define cancer subtypes, recur-
rence  of  disease  and  response  to  specific  therapies 
[14]. Several assays showed that the signature of stage 
I NSCLC alone  could not reveal differences in out-
come in patients with stage II disease, which indicated 
that existence of additional molecular mechanisms in 
more advanced lung carcinomas [15,16,17]. The vari-
ous signal transduction pathways in LAD of different 
stages might help to find out the pivotal events in the 
tumor development.  
DNA  microarray  technology  provides  a  suffi-
cient  screening  tool  for  searching  differentially  ex-
pressed genes (DEGs) by  investigating the gene ex-
pression  profile  [18].  However,  many  microar-
ray-based studies showed that some results were not 
reproducible  [19].  It  commonly  resulted  from  im-
proper analysis and insufficient control of false posi-
tives, and was often exacerbated by the small sample 
sizes [20]. Meta-analysis is an efficient, indispensable 
and inexpensive supplementary tool for the microar-
ray  data  analysis.  It  uses  statistical  techniques  to 
combine results from independent but related studies. 
Integrated information from multiple studies can im-
prove the reliability and generalizability of the com-
bined results, and the enhanced statistical power fa-
vored a more precise estimate of DEGs. The method 
of meta-analysis was gradually improved to achieve 
different  research  goals,  such  as  robustifying 
cross-platform classification, and identifying overlaps 
from heterogeneous datasets of different cancers and 
tissues [21]. With the increasing number of available 
free  public  microarray  datasets,  meta-analysis  of 
multiple datasets has been widely used and proved to 
be a useful method in searching DEGs [22].  
 Various studies had used microarray gene ex-
pression  profiles  to  analyze  oncogenic  pathway  [3]. 
Several molecular pathways involved in NSCLC ma-
lignancy  have  been  revealed,  such  as  Epidermal 
Growth  Factor  Receptor  pathway  (EGFR)  and  Bcl-2 
pathway  [23].  However,  few  studies  focused  on 
changes on the pathway level in cancer development. 
Most LADs are consist of more than one subtype [6]. 
In order to find the common features of these sub-
types  on  pathway  level,  we  performed  the  me-
ta-analysis of the LAD microarray data to analyze the 
progression-associated genes and pathways in tumor 
development  by  stage  comparison  rather  than  sur-
vival signature analysis. Four LAD datasets was in-
cluded  in  our  analysis  to  search  significantly  regu-
lated  genes  and  pathways  in  comparisons  between Int. J. Biol. Sci. 2011, 7 
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normal  lung  tissues  and  LADs  of  different  stages, 
which  was  based  on  the  TNM  stage  classification. 
Real-time PCR experiment was applied to verify the 
expression of genes in different LAD cell lines. 
 
Material and Method 
Meta-analysis 
Data collection 
Data used in this study were publicly available 
from  cDNA  and  oligo  (Affymetrix)  microarrays  ex-
periments on LADs. Studies were eligible if they ful-
filled  all  the  following  criteria:  every  single  dataset 
must  contain  at  least  one  stage  with  ≥3  of  tumor 
samples, as well as at least ≥3 of normal tissues; stage 
information  would  be  available  for  tumor  samples. 
The raw data (CEL files) of oligo microarray and the 
normalized  data  of  cDNA  microarray  were  down-
loaded from the website. The tumor adjacent normal 
tissues were defined as normal tissue. 
Four datasets, encompassing 353 patients, were 
eligible for our meta-analysis (Table 1). Dataset1 and 
dataset3  were  downloaded  from 
http://www.broad.mit.edu/cgi-bin/cancer/datasets
.cgi  [28]  and  http://caarraydb.nci.nih.gov/caarray/ 
publicExperimentDetailAction.do?expId=1015897558 
050283  [29],  respectively.  Both  dataset2  (GSE3398, 
[30]) and dataset4 (GSE10072, [31]) were downloaded 
from NCBI (http://www.ncbi.nlm.nih.gov/). Dataset 
2 contained fewer samples than other datasets. 
 
 
Table 1. LAD gene expression datasets used in meta-analysis of microarrays 
  Author  Normal  IA  IB  IIA  IIB  IIIA  IIIB  IV  Array type  Plate form  Total 
clones 
Unique 
clones 
Dataset1  Bhattacharjee 
et al. 
17  29  40  4  17  6  3  2  oligo  GPL91  12625  8889 
Dataset2  Garber et al.  5  5  4  1  1  6  0  10  cDNA  GPL2832/GPL2
905 
24192  9296 
Dataset3  Beer et al.  10  45  23  0  0  15  3  0  oligo  GPL80  7129  5479 
Dataset4  Landi et al.  49  5  17  3  18  9  3  3  oligo  GPL96  22283  12821 
Total    81  84  84  8  36  36  9  15         
The unique clones are identified with ref sequence ID. 
 
 
 
Data processing  
All the CEL files, which recorded the raw fluo-
rescence intensity of the oligo microarrays, were pre-
processed with the Robust Multichip Average (RMA) 
algorithm to normalize the data and generate more 
precise intensities for each probe. The calculation was 
performed with R language software and „affy‟ pro-
gram  package  from  Bioconductor 
(http://www.bioconductor.org/).  For  cDNA  micro-
array, the normalized data were applied directly in 
the following analysis and missing data were allowed. 
We  transformed  the  diverse  identifier  of  each  gene 
from the different datasets into one form-ref sequence 
ID  using  program  from  http://genome-www5. 
stanford.edu/cgi-bin/source/sourceBatchSearch. The 
average value was calculated if a gene appeared more 
than once in a single dataset. 
Data analysis 
We  performed  the  meta-analysis  referred  to 
Rhodes et al.‟s method [24]. The significance assess-
ment was based on two null hypotheses that no genes 
were up-regulated or no genes were down-regulated 
in  LADs.  Firstly,  we  performed  10  000  one-sided 
random permutation t tests for every single dataset 
between normal samples (group 1) and tumor sam-
ples  (group  2,  such  as  stage  IA).  For  an  individual 
gene,  a  t  statistic  (t)  was  calculated  and  compared 
with  10  000  t  statistics  generated  by  randomly  as-
signing  the  samples,  and  each  gene  obtained  a 
study-specific  P(t)  in  every  single  dataset.  P(t)s 
equaled  to  zero  were  set  to  0.0001.  Secondly,  the 
overlapping  genes  from  the  different  datasets  com-
binations  were  selected  and  the  relevant  summary 
statistic  (S)  was  calculated  with  the  P(t)s  from  pre-
ceding  random  permutation  t  tests  for  each  gene, 
based on Fisher‟s method for combining P values [25]. 
These actual S statistics then compared to 1 000 000 S 
statistics generated by randomly selecting a P(t) from 
each  dataset.  Finally,  to  control  the  false  discovery 
rate (FDR), the genes were sorted by the P(s) values 
and  a  new  statistic  Q  was  calculated  according  to Int. J. Biol. Sci. 2011, 7 
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Benjamini and Hochberg‟ method [26] (Figure 1). 
A designated gene might not exist in all eligible 
datasets, the meta-analysis of each comparison (e.g. 
Normal vs stage IA, Normal vs stage IB, etc.) (Figure 
2)  was  performed  in  different  dataset  combinations 
(every two datasets, every three datasets etc.) to retain 
information  as  much  as  possible  (Figure  1).  Conse-
quently, each gene might obtain several Q values and 
only the smallest Q value was used for the following 
analysis.  All  the  calculation  was  implemented  with 
perl software. 
 
 
 
 
Figure 1. A model for meta-analysis of microarrays (Normal vs stage IA). Firstly, 10,000 one-sided random permutation t 
tests were performed between normal group and stage IA group in each dataset, and generated a series of P values. Secondly, 
the datasets were assigned to different combinations, such as all four datasets (ABCD). For a given combination, the 
overlapping genes and their corresponding P values were picked out. Thirdly, the random permutation s test (Formula 1) 
was calculated in every combination and the significant changed genes (up- or down- regulated in tumors compared with 
normal tissues) were screened with Q values (Q<0.1) (Formula 2). Formula 1: S = -2*log (p1) + -2*log (p2) + … + -2*log (pn). 
[p is P(t) value; n is the total number of datasets]. Formula 2: Q = (P*n)/i. [P is P(s) value; n is the total number of genes; i is the index 
of sorted P (s)]. Int. J. Biol. Sci. 2011, 7 
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Figure 2 Flow diagrams for data analysis. The datasets were assigned into several comparison groups between normal 
tissues and LADs in different stages. The meta-analysis was performed in each comparison to generate significantly changed 
genes (see Figure 1 for details), which were reserved for GO and Pathway analysis. The randomly selected DEGs from 
Normal vs IA and Normal vs IB were tested in Calu-3 lung adenocarcinoma and WI-38 normal lung cell lines using real-time 
PCR; DEGs from Normal vs IIIA and Normal vs IIIB were validated with H1299 lung adenocarcinoma and WI-38 cell lines by 
real-time PCR.   
 
 
 
Pathway and GO analysis 
All the genes were imported into the pathway 
and GO analysis of the Genmapp software, which was 
downloaded  from  the  web 
(http://www.genmapp.org/  version  2.1,  Hs-std 
20070817). Genes with Q<0.1 in the up-regulation or 
down-regulation  groups  were  considered  to  be 
changed significantly. The remaining was considered 
as background genes. The associated pathways and 
GO were sorted by the Z score. The pathway was ex-
cluded if the number of hits ≤3. The pathway and GO 
with Z score >1.96 was considered to be significant in 
the Genmapp result. 
Experiments 
Cell culture 
Lung  adenocarcinoma  cell  lines  (Calu-3  and 
H1299) and lung  normal fibroblast cell line (WI-38) 
were obtained from Cell Bank of Type Culture Col-
lection  of  Chinese  Academy  of  Sciences  (Shanghai, 
China). Calu-3 cells were grown in Eagle‟s Minimum 
Essential  Medium  (Invitrogen,  Carlsbad,  CA,  USA), 
H1299  cells  were  grown  in  RPMI-1640  Medium 
(4.5g/L  glucose)  (Invitrogen),  and  WI-38  cell  were 
grown  in  Eagle‟s  Minimum  Essential  Medium,  re-
spectively. All the Medium were supplemented with 
10%  fetal  bovine  serum  (Clarkbio,  Seabrook,  MD, Int. J. Biol. Sci. 2011, 7 
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USA) and antibiotics (100U/ml penicillin, 100 μg/ml 
streptomycin)(Invitrogen) and the cells were placed in 
a humidified atmosphere of 5% CO2 at 37 °C.  
 
Table 2.  The selected 18 candidate genes and primer 
sequence used in real-time PCR 
  Gene Sym-
bol 
Primer Sequence 
A group  LIMK1  5'CCTGCGGAGCCTCAAGAA 3' 
    5'GACGATCCCAAAGGAGAACAC 3' 
  TYRP1  5'TATGATACCCTGGGAACACT 3' 
    5'TTCCAAGCACTGAGCGACAT 3' 
  DDR1  5'GACACTATCCTCATCAACAACCG 3' 
    5'CTGGCTTCTCAGGCTCCATAT 3' 
  RUNX3  5'TGGCAGGCAATGACGAGA 3' 
    5'AGTGATGGTCAGGGTGAAACTC 3' 
  GRB7  5'GCAGGGCTTGGTAGACGG 3' 
    5'CCTCCTCCTCGCTCGG 3' 
  SMARCC1  5'ACCTCCTCCTACTCCTCATTTTA 3' 
    5'ACTGGTTTTTCCTTGTTTTTCTC 3' 
  CEACAM1  5'GGCATTGTGATTGGAGTAGTGG 3' 
    5'TTAGGTGGGTCATTGGAGTGG 3' 
  CTGF  5'CTGCCCTCGCGGCTTAC 3' 
    5'GGAGATGCCCATCCCACA 3' 
  NT5E  5'CCAATGGTGGAGATGGGTT 3' 
    5'CGACCTTCAACTGCTGGATAA 3 
B group  MPP1  5'CTTCTGCGAGATGACCCTCA 3' 
    5'CACAGTATTCAATGGATGCGATA 3' 
  GPX3  5'CTGACGGGCCAGTACATTG 3' 
    5'GGTCGGACATACTTGAGGGT 3' 
  SPP1  5'GGGAGGGCTTGGTTGTCA 3' 
    5'AATCACTGCAATTCTCATGGTAGT 3' 
  ACE  5'CTGCACCGTCACTACGGG 3' 
    5'GAAGGGAAGGGCACCACC 3' 
  VIM  5'ACTTTTCCTCCCTGAACCTGA 3' 
    5'TCGTGATGCTGAGAAGTTTCG 3' 
  HMGA1  5'AGCGAAGTGCCAACACCTAA 3' 
    5'TGCCCTCCTCTTCCTCCTT 3' 
  STAT5A  5'GCCTGTCCGTGTCCTGGT 3' 
    5'GTGGGGCTTGTGGTGCTT 3' 
  ID3  5'GTCCTGACACCTCCAGAACGC 3' 
    5'GGATTTGGTGAAGTCAAGTGGG 3' 
  CDKN1C  5'GCTGCGGTGAGCCAATTT 3' 
    5'CGGTTGCTGCTACATGAACG 3' 
Control  GAPDH  5'TGAAGGTCGGAGTCAACGG 3' 
    5'TGGGTGGAATCATATTGGAACA 3 
  18SrRNA  5'TTGGTGGAGCGATTTGTCTG 3' 
    5'ATCTCGGGTGGCTGAACG 3' 
 
Real-time PCR  
The total RNA of Calu-3, H1299 and WI-38 cells 
were extracted using Trizol reagent (Invitrogen) and 
the  cDNA  was  synthesized  with  superscript  III  re-
verse transcription PCR kit (Invitrogen). Quantitative 
real-time  PCR  was  performed  in  7900HT  Fast  Re-
al-time PCR System (Applied Biosystems, Foster, CA, 
USA)  with  2X  HotSybr  PCR  Reaction  Mix  (NuStar 
Laboratory,  San  Francisco,  CA,  USA).  In  order  to 
avoid  DNA  contamination,  all  the  oligo  nucleotide 
primers were designed to target to different exons of 
the selected genes except for 18SrRNA, which has one 
single exon. The gene symbols and primers sequences 
of the  amplified genes were shown in Table  2. The 
18SrRNA and GAPDH were used as the endogenous 
controls. All PCR reactions were carried out with the 
following program: 2 min at 55 °C, 10 min at 95°C, 
and 40 cycles of 15s at 95°C and 1min at 60°C. After 
the  amplification,  the  melting  curve  analysis  was 
performed and the threshold cycles (Ct) was deter-
mined by the software SDS 2.3 (Applied Biosystems). 
The fold change of gene expression in WI-38 cells rel-
ative to Calu-3 or H1299 cells was calculated using 
2-⊿⊿CT method [27]. 
Results 
Common gene expression changes in different 
stages 
Totally,  four  datasets,  encompassing  353  pa-
tients, were eligible for our meta-analysis (Table 1). 
Different combinations of datasets had different sets 
of  overlapping  genes,  so  we  performed  the  me-
ta-analysis for each possible combination (Figure 1). 
Genes  with  a  Q<0.1  which  significantly  changed  in 
mRNA expression level in different comparisons were 
defined as DEGs. We counted the number of signifi-
cant Qs for each gene. Thus, a significant gene had at 
least one significant Q value. The overall Q value and 
the frequencies of the significant Qs were informative 
to evaluate the reliability of the result. We performed 
six comparisons between normal tissues and LADs in 
different stages (Figure 2). The comparison between 
normal and stage IV revealed no DEGs. In total, the 
expression of 1 838 DEGs were found in the six dif-
ferent comparisons (Additional file 1: Supplementary 
Table 1A and 1B), and 918 genes were up-regulated 
and 920 genes were down-regulated at least once.  
The datasets, sample  numbers, and number  of 
DEGs in different comparisons were listed in Table 3. 
More  DEGs  might  be  obtained  from  more  datasets 
combinations. Both Normal vs IIA and Normal vs IIB 
had  2  datasets,  but  more  DEGs  were  found  in  the 
comparison  of  Normal  vs  IIB.  After  examining  the 
samples of every stage, we found that stage IIA had 
fewer samples (4 samples in dataset1 and 3 samples in 
dataset4) than that of stage IIB (17 samples in dataset 1 Int. J. Biol. Sci. 2011, 7 
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and 18 samples in dataset 4). The comparison Normal 
vs IIIB included only 9 stage IIIB LAD samples from 3 
datasets. Although fewer datasets was included in the 
comparison of Normal vs IIB, more DEGs (718) were 
found  compared  with  that  of  Normal  vs  IIIB  (321). 
Thus, smaller sample size might lead to fewer DEGs. 
Many  well-known  metastasis-associated  genes 
were  found,  such  as  ERBB2,  PLAU  and  MMP9 
[28,29,30]. Interestingly, some gene family members 
had similar regulation tendency. As shown in Table 4, 
eight genes (e.g. IL6R, IL4R and IL7R) of interleukin 
receptor  family,  thirteen  genes  (e.g.  COL13A1  and 
COL1A1) of collagen family, eight genes (e.g. ITGB4 
and  ITGAV)  of  integrin  family,  eight  genes  (e.g. 
MMP9  and  MMP13)  of  metalloproteinase  family, 
thirteen genes of histone cluster, five genes of mini-
chromosome  maintenance  (MCM)  complex  compo-
nent  families,  and  four  genes  of  inhibitor  of  DNA 
binding (Id) family were significantly changed in the 
mRNA  expression  level  compared  with  normal  tis-
sues. Those gene families had been shown to be in-
volved in cancer progression. The high proliferation 
state  of  cancer  cells  is  associated  with  an  increased 
expression of MCM proteins that can be detected in 
both malignant precursor lesions and carcinomas [31]. 
As the synthesis of histones is tightly coupled with 
DNA replication during S-phase of the cell cycle, his-
tone  mRNA  level  is  often  a  proliferative  marker  in 
cancers  [32,33].  The  overexpression  of  ITGAV  had 
been found in several types of tumors to promote the 
invasion or be related with metastasis and late-stage 
[34,35].  The  expression  of  β4  increases  significantly 
during malignant progression in squamous carcino-
mas  of  multiple  tissues,  including  head  and  neck, 
skin, cervix, and lung [36]. Type IV collagen is a major 
component in most basement membranes. During the 
process of stromal invasion of lung adenocarcinoma, 
type IV collagen of alveolar basement membrane is 
remodelled  from  the  complete  type,  composed  of 
1(IV)/2(IV)/3(IV)/4(IV)/5(IV)  chains,  to  the  incom-
plete type, composed of only 1(IV)/2(IV) chains[37]. 
In our study, the expression levels of COL4A3 and 
COL4A5 (corresponding to the type IV collagen 3/4 
chains) were down-regulated in the LADs.  
 
Table 3. Datasets, samples and DEGs (Q<0.1) in the six comparisons 
Comparisons  Datasets  Normal  Tumor  DEGs  Pathways(Z>1.96) 
Normal vs IA  4  81  84  1004  42 
Normal vs IB  4  81  84  1419  65 
Normal vs IIA  2  66  7  106  4 
Normal vs IIB  2  66  35  718  42 
Normal vs IIIA  4  81  36  928  47 
Normal vs IIIB  3  76  9  321  35 
 
 
Table 4. The regulation of gene family members 
Gene Family  Up-regulation  Down-regulation  Proportion 
Histone cluster  HIST1H1C,HIST1H2AC,HIST1H2AE,HIST1H2AG,HIST1H2B
D,HIST1H2BE,HIST1H2BF,HIST1H2BI,HIST1H2BK,HIST1H3
H,HIST2H2AA4,HIST2H2BE,HIST4H4 
  13/0 
Matrix metallopeptidase  MMP1,MMP9,MMP11,MMP12,MMP13,MMP14,MMP15,MMP
17 
  8/0 
Interleukin receptor    IL1R1,IL3RA,IL4R,I
L6R,IL7R,IL10RA,IL
11RA,IL18R1 
0/8 
Minichromosome maintenance 
complex component 
MCM2,MCM3,MCM4,MCM5,MCM6    5/0 
Inhibitor of DNA binding    ID1,ID2,ID3,ID4  0/4 
Collagen  COL11A1, COL10A1, COL3A1, COL5A2, COL1A2, COL9A3, 
COL9A2, COL1A1, COL5A1, COL7A1 
COL4A3,COL4A5,C
OL13A1 
10/3 
Integrin  ITGAV, ITGB4  ITGA5,ITGA6,ITGA
7,ITGA8, ITGAL, 
ITGAX, 
2/6 
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Intriguingly,  we  found  that  most  of  the  genes 
from  the  same  gene  family  were  up-regulated  (or 
down-regulated). The similar trend of expression of 
these  gene  family  members  suggested  coordinate 
regulation. Binding sites for ETS or AP-1 transcription 
factors are found in the promoters of MMP family and 
these transcription factors have been reported to reg-
ulate  MMP  gene  expression  [38].  Besides,  several 
members  of  S100,  HOX,  CLDN,  FOX,  CDK  family 
were among the DEGs. Genes with unknown func-
tions in LAD development were also found. 
Pathways and GO in different stages 
We  performed  pathways  and  GO  categories 
analyses  from  the  six  comparisons  separately  using 
the Genmapp software. The pathways and GOs with 
Z score > 1.96 were considered significant and ranked 
by their appearing times in the six comparisons (Ad-
ditional file 1: Supplementary Table 2 and Table 3).  
Table  5  showed  the  top  ten  GO  categories  of  the 
Genmapp result. Most of them were involved in the 
cancer  development,  plasma  membrane  and 
co-receptor/soluble  ligand  activity.  Table  6  showed 
the top twenty-six pathways, which were significant 
in at least four comparisons, with rank value equal to 
0 or 2.  
Besides  the  well-known  cancer-related  path-
ways,  the  Adipogenesis,  Circadian  exercise,  and  Id 
pathway  are  important  pathways  revealed  by  our 
analysis. White adipose tissues could  synthesize and 
secrete adipokines, which played important roles in 
inﬂammation,  angiogenesis,  lipid  metabolism,  cell 
proliferation, apoptosis, and cell differentiation [39]. 
The adipogenesis pathway had not been reported to 
be  a  significantly  regulated  pathway  (SRP)  in  LAD 
before. Our result indicated it might play important 
roles  in  the  development  of  LAD.  Circadian  clock 
genes were involved in cell proliferation, apoptosis, 
cell  cycle  control,  and  DNA  damage,  and  many  of 
them were silenced in cancer cells [40,41,42,43,44]. Id 
pathway included four important inhibitor of differ-
entiation/DNA  binding  (ID)  family  members,  ID1, 
ID2, ID3 and ID4, which had been reported to be crit-
ical in cell differentiation and proliferation [45].  
 
 
Table 5.  Top 10 GOs derived from the six comparisons and its corresponding Z scores 
GO  Normal vs IA  Normal vs IB  Normal vs IIA  Normal vs IIB  Normal vs IIIA  Normal vs IIIB 
coreceptor\soluble ligand activity  5.328  4.434  17.157  6.381  5.551  9.573 
organ development  7.546  8.741  6.988  7.613  8.211  8.94 
plasma membrane  10.17  7.824  4.988  8.097  8.055  7.088 
system development  7.92  7.609  7.15  7.1  7.259  8.943 
multicellular organismal process  7.334  7.096  7.341  6.669  6.952  10.309 
multicellular organismal devel-
opment 
7.058  7.078  7.254  6.515  7.17  8.867 
plasma membrane part  9.112  7.037  5.561  6.942  7.899  7.065 
developmental process  7.759  8.469  5.512  7.006  7.218  7.351 
anatomical structure development  7.326  6.911  6.289  6.575  6.769  8.151 
platelet alpha granule  5.328  4.434  8.52  6.381  5.551  9.573 
 
 
Table 6. Top 26 pathways derived from the six comparisons and its corresponding Z scores. 
Pathway  Normal vs 
IA 
Normal vs 
IB 
Normal vs 
IIA 
Normal vs 
IIB 
Normal vs 
IIIA 
Normal vs 
IIIB 
Rank 
Hs_2-Tissues-Internal_Organs  8.632  6.741  5.424  5.966  5.922  5.062  0 
Hs_Adipogenesis  3.93  2.968  3.138  3.359  2.775  4.004  0 
Hs_1-Tissue-Blood_and_Lymph  8.638  6.16  2.583  4.535  6.702  /  1 
Hs_2-Tissues-Blood_and_Lymph  6.192  5.84  /  4.442  6.166  3.402  1 
Hs_IL-5_NetPath_17  6.048  6.114  /  5.106  5.178  4.192  1 
Hs_Complement_and_Coagulation_Cascades_
KEGG 
5.673  4.175  /  4.042  6.004  3.947  1 
Hs_TGF-beta-Receptor_NetPath_7  5.339  5.428  /  3.432  4.383  2.822  1 
Hs_2-Tissues-Endocrine_and_CNS  4.963  3.81  /  3.74  4.653  3.937  1 Int. J. Biol. Sci. 2011, 7 
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Hs_Circadian_Exercise  4.825  3.027  /  3.572  5.621  4.016  1 
Hs_Peptide_GPCRs  4.297  2.135  /  2.674  3.802  3.449  1 
Hs_1-Tissue-Internal_Organs  4.034  2.054  /  2.697  3.124  3.485  1 
Hs_Prostaglandin_synthesis_regulation  3.467  4.481  /  2.554  3.699  3.683  1 
Hs_Statin_Pathway_PharmGKB  3.244  2.362  /  4.215  3.439  4.179  1 
Hs_IL-3_NetPath_15  2.775  2.519  /  2.709  2.037  2.427  1 
Hs_Calcium_regulation_in_cardiac_cells  2.701  3.39  /  2.869  2.217  3.311  1 
Hs_Focal_adhesion_KEGG  2.355  4.011  /  3.331  5.787  3.706  1 
Hs_Eicosanoid_Synthesis  2.322  2.867  /  2.282  2.491  5.242  1 
Hs_Glycolysis_Gluconeogenesis  2.088  2.207  /  2.679  3.253  3.688  1 
Hs_Oxidative_Stress  /  3.168  /  3.948  3.145  2.21  2 
Hs_Glycolysis_and_Gluconeogenesis  /  2.275  /  2.306  3.153  2.833  2 
Hs_Integrin-mediated_cell_adhesion_KEGG  /  2.758  /  2.277  2.687  3.477  2 
Hs_Matrix_Metalloproteinases  2.982  2.524  /  2.647  1.953  /  2 
Hs_Id_NetPath_5  2.76  3.26  /  /  2.04  2.376  2 
Hs_Striated_muscle_contraction  2.749  3.122  /  1.986  /  3.968  2 
Hs_IL-7_NetPath_19  2.25  3.405  /  3.901  4.01  /  2 
Hs_EGFR1_NetPath_4  2.141  2.625  3.038  /  /  2.714  2 
The “/” suggested that the Z score<=1.96 
 
 
Validation of common cancer genes by real-time 
PCR 
Normal lung fibroblast cell line WI-38 and two 
LAD  cell  lines  Calu-3  and  H1299  were  used  for 
qRT-PCR gene expression validation. Calu-3 had me-
dium tumorigenicity but no metastasis characteristic, 
while  H1299  had  high  tumorigenic  and  metastasis 
capacity. The genes in group A (Table 2) were tested 
by WI-38 and Calu-3 cell lines. They were randomly 
selected from the DEGs from comparisons of Normal 
vs  IA  and  Normal  vs  IB,  but  did  not  significantly 
changed in mRNA expression level in comparisons of 
Normal  vs  IIIA  and  Normal  vs  IIIB;  the  genes  in 
group  B  were  verified  with  WI-38  and  H1299  cell 
lines.  They  were  DEGs  (Q<0.05)  randomly  selected 
from the comparisons of Normal vs IIIA and Normal 
vs IIIB.  
It  was  important  to  notice  that  in  our  me-
ta-analysis, housekeeping genes GAPDH and HPRT1 
were overexpressed in LAD compared to normal tis-
sues. The result was in consistent with Nguewa et al.‟s 
study, in which they found the GAPDH and HPRT1 
were not good internal control genes in lung tissue 
specimens, but the two genes could be used as inter-
nal controls when lung cell lines were applied for the 
experiment  [46].  Our  qRT-PCR  assay  demonstrated 
that the expression level of GAPDH was stable in the 
three  different  lung  cell  lines.  Thus,  we  used  both 
GAPDH and 18SrRNA as internal controls. The genes 
with log 2 ratios  ≥1 or ≤−1 were determined as sig-
nificantly  changed  (overexpressed  or  underex-
pressed). As shown in Figure 3, if we considered the 
significant  changes  in  expression  level,  the  two 
methods (meta-analysis and real-time PCR) showed 
77% consistency in group A and 66% in group B; If we 
considered the expression tendency, the two methods 
had  matched  over  90%.  SPP1  showed  the  opposite 
regulation tendency (Figure 3B). However, a homo-
zygous partial deletion of p53 protein was existed in 
H1299  cell  line,  which  might  result  in  the 
down-regulation  of  SPP1,  a  target  of  p53  and  was 
down-regulated when p53 was silenced [47]. Similar 
result was obtained when used 18SrRNA as internal 
control  (data  not  shown).  Our  analysis  suggested  a 
possible relationship between these genes and LAD 
metastasis.  
Sample size, DEGs and pathways 
Table  3  showed  that  small  sample  size  in  the 
comparison would lead to fewer DEGs. To investigate 
the effects of sample size, we compared the Q values 
of meta-analysis combining only two datasets for the 
18  genes  tested  with  real-time  PCR.  The  results  in 
Figure 4 showed that the Q values from meta-analyses 
combining Dataset2, the one had the smallest sample 
size, always showed higher Q value than those anal-
yses combined without Dataset2. Thus, meta-analysis 
integrating  small  sample  size  dataset  led  to  fewer 
DEGs, as well as false negative. 
The  pathway  calculation  in  Genmapp  was  in-
fluenced  by  the  number  of  DEGs  and  total  genes. 
Since  we  imported  the  same  total  genes  in  the  six 
comparisons, the calculation of significantly regulated 
pathways  (SRPs)  were  mainly  determined  by  the 
DEGs. More DEGs would result in more SRPs (Table Int. J. Biol. Sci. 2011, 7 
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3).  The  comparison  Normal  vs  IIA  revealed  only  4 
SRPs which might arise from fewer DEGs. Thus, we 
only compared the SRPs in other five comparisons.  
Interestingly, if comparison Normal vs IIA was 
deleted in the pathway analysis, we found that Oxi-
dative Stress, Glycolysis/Gluconeogenesis and Integ-
rin-mediated cell adhesion pathways were not signif-
icant in the comparison of Normal vs IA, but were 
significant (Z>1.96) in other four comparisons. 
 
 
 
Figure 3 Real-time PCR validations of 18 candidate genes. Bars represent log2 fold changes of the selected genes with 
differential expression between A) Calu-3 and WI-38, B) H1299 and WI-38. Positive represents up-regulated and negative 
represents down-regulated in tumor cells compared with normal lung cells. The group A gene TYRP1, DDR1, RUNX3, GRB7, 
SMARCC1, CEACAM1, CTGF showed >2-fold change in mRNA expression level, which were in consistency with the result of 
meta-analysis. NT5E and LIMK1 showed no significant change in mRNA expression; the fold changes were 1.19 and 1.1, 
respectively. The group B gene MPP1, GPX3, ACE, STAT5A, ID3 and CDKN1C showed >2-fold change in mRNA expression 
level, which were in consistency with the result of meta-analysis. The expression of VIM and HMGA1 had the same up- and 
down- regulation tendency compared with the meta-analysis result, but showed no significant change in real-time PCR 
analysis. SPP1 showed the opposite regulation tendency. Int. J. Biol. Sci. 2011, 7 
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Figure 4 Q values of two datasets combinations for 18 genes A) the Q values of stage IIIA from all two datasets combi-
nations for 9 genes in group B. All the Q values from the meta-analyses integrating Dataset2 are on the top part, which 
indicated datasets with smaller sample size contributed to false negatives; B) the Q values of stage IB from all two datasets 
combinations for 9 genes in group A.. The Q values for those integrated Dataset2 tend to be on the top part too. Com-
bination integrated Dataset2 were shown as solid. Note that Dataset2 did not contain the genes ACE and STAT5A. The 
result of stage IA was shown in Additional file 2: Supplementary Figure 1. 
 
 
Many types of cancer cell had increased levels of 
reactive  oxygen  species  (ROS),  which  could  cause 
DNA damage and might trigger tumor initiation, and 
the ROS-induced oxidative stress could contribute to 
tumor development not only through genetic, but also 
through epigenetic mechanisms [48,49]. In our analy-
sis,  two  important  anti-oxidant  genes  in  Oxidative 
Stress  pathway  exhibit  varied  expression  between 
Stage IA and others. The ECSOD (SOD3), a mainly 
extracellular superoxide dismutase, was not a DEG in 
normal vs stage IA, while GCLC, which catalyses the 
initial rate limiting step of GSH synthesis, was signif-Int. J. Biol. Sci. 2011, 7 
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icantly overexpressed in stage IB, IIB, IIIA and IIIB 
compared with normal tissues, other than in stage IA.  
Most tumor cells displayed high rates of glycol-
ysis, which could provide more nutrition and energy 
for  the  proliferation  [50].  The  LDHA,  an  important 
gene  in  Glycolysis/Gluconeogenesis  pathway,  was 
significantly overexpressed in stage IB, IIB and IIIA, 
but not in stage IA, compared with normal tissues. 
Integrin-mediated cell adhesion pathway, which me-
diated  interaction  between  the  tumor  cell  and  the 
matrix, was closely associated with metastasis [51]. In 
our study, integrin alpha V (ITGAV) was significantly 
up-regulated in stage IB and IIB, but not in stage IA. 
Discussion 
The development of lung cancer was a complex 
and gradual process. In this study, we combined four 
LAD  gene  expression  studies  based  on  Affymetrix 
and  cDNA  microarray  platforms,  to  find  LAD  pro-
gression-associated  genes  and  pathways  using  me-
ta-analysis  strategy.  The  increased  sample  size  was 
intended to control false positives and increase statis-
tical power in detecting important DEGs.  
Different  stages  of  LAD  were  compared  with 
lung  normal  tissues  to  preserve  information  on  the 
progress  of  metastasis.  GO  analysis  indicated  that 
many  genes  were  involved  in  carcinogenesis  and 
metastasis process-related categories, such as cell mi-
gration (CEACAM1, CXCL12, CTGF), cell proliferation 
(HDGF,  MDK),  cell  motility  (SPP1),  cell  adhesion 
(CDH1),  and  angiogenesis  (ANGPT1).  There  were 
several  well-known  cancer-related  pathways  were 
found,  which  included  TGF-beta,  Focal  adhesion, 
EGFR,  Fas,  TNF-alpha-NF-kB,  MAPK,  p38  MAPK, 
Wnt,  Matrix  Metalloproteinases  (MMP),  Integ-
rin-mediated  cell  adhesion  and  IL  pathways[52]. 
Some of them played significant roles in the progress 
of many kinds of tumors. Specially, the focal adhe-
sion, MMP, integrin-mediated cell adhesion, and reg-
ulation of Actin Cytoskeleton pathways were closely 
related  to  metastasis,  which  mediated  interaction 
between the tumor cell and the matrix [28,29,51,53]. 
Adipogenesis,  Circadian  exercise,  and  Id  path-
way are important pathways revealed by our analysis. 
Typical  functions  of  white  adipose  tissue  were  tri-
glycerol storage and energy utilization. Recent studies 
indicated that white adipose tissue is a multi- func-
tional endocrine organ that synthesizes and secretes 
adipokines (cytokine-like proteins). Many adipokines 
have  a  pivotal  role  in  inﬂammation,  angiogenesis, 
lipid metabolism, cell proliferation, apoptosis, and cell 
differentiation [39]. On the other hand, inducers de-
rived  from  cancer  cells  signiﬁcantly  induced  or  en-
hanced  adipogenesis  [54].  Specially,  it  has  recently 
been shown that MMP11 is induced in adipose tissue 
by cancer cells as they invade their surrounding en-
vironment  [55].  Additionally,  MMP2  and  MMP9, 
which had been proved to take important effect on 
metastasis, were also produced and secreted by adi-
pocytes in the adipose differentiate [28,56]. 
There  is  growing  evidence  that  many  cellular 
clock genes were silenced in cancer cells[41]. Loss and 
dysregulation of PER1 and PER2, two important cir-
cadian rhythm genes, have been found in many types 
of human cancers [40,41,42,43,44]. PER1 was found to 
be silenced in 70% NSCLC patients [57]. ID1, ID2, ID3 
and ID4 in Id pathway had been reported to be critical 
in cell differentiation and proliferation [45]. Only in 
the last two years, the ID genes had been reported in 
the small cell lung cancer (ID1, ID2, ID3 and ID4) and 
NSCLC (ID2) [58,59]. 
In  addition,  pathways  involved  in  metabolism 
were revealed to be associated with LAD progress in 
our  study.  Prostaglandin,  a  ubiquitous  hormone  in 
human body, could stimulate human lung carcinoma 
cell  growth,  and  the  critical  genes  in  prostaglandin 
synthesis had been proved to be associated with car-
cinogenesis  [60,61,62].  The  statin  (a  cholester-
ol-lowering agent) pathway functioned in the choles-
terol metabolism and circulation had been found to be 
related  to  cancer  development  [63,64,65,66].  Mean-
while, the metabolism of amino acid, nucleotide and 
other materials might also be accelerated during the 
process of metastasis. We identified a group of genes, 
which might associate with the complicated metasta-
sis process in LAD. These genes were involved in a 
wide  pathway  network.  They  provided  more  infor-
mation,  and  supplemented  the  well-known  can-
cer-associated pathways. 
The additional molecular mechanisms might ex-
ist in more advanced lung carcinomas such as stage II 
[15,16,17]. However, no comparison of the potential 
molecular  mechanisms  had  been  made  among  dif-
ferent stages of LAD. In our study, Oxidative stress, 
Glycolysis/Gluconeogenesis  and  Integrin-mediated 
cell adhesion pathways were showed to be significant 
in stages other than IA.  
There were evidences that compared with nor-
mal counterparts, many types of cancer cell had in-
creased  levels  of  reactive  oxygen  species  (ROS) 
[48,49]. Mori et al.‟s study demonstrated that the in-
vasive  potential  could  be  induced  under  long-term 
oxidative stress in mammary epithelial [67]. This an-
tioxidant enzyme in Oxidative stress pathway was the 
major determinant in decreasing extracellular oxidant 
stress and might have fundamental effects on the ex-
tracellular redox state of lung tumors with potential 
consequences on tumor behavior  [68]. Increased in-Int. J. Biol. Sci. 2011, 7 
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tracellular  ROS  (lipid  peroxidation)  and  superoxide 
production  were  related  with  down-regulated 
ECSOD in NSCLC [69]. Several studies suggested that 
cells with active c-Myc may survive the ROS stress by 
up-regulating  glutathione  (GSH)  synthesis,  an  im-
portant  antioxidant  in  Oxidative  stress  pathway  to 
minimize the oxidative damage [70]. GCLC catalyses 
the initial rate limiting step of GSH synthesis. Ray et 
al.‟s  assay  demonstrated  that  the  up-regulation  of 
GCLC mRNA in lung cancer cell lines (H292) could be 
induced by ROS [71].  
Despite in the presence of a high O2 concentra-
tion, the glycolysis was enhanced in tumor cells, and 
provided more nutrition and energy for the prolifera-
tion  [50].  Most  tumor  cells  displayed  high  rates  of 
glycolysis, aerobic or anaerobic, and many glycolytic 
tumor cells were also found to be aggressive [72]. Wu 
et al.‟s study demonstrated that A549 cells displayed a 
dependency  on  glycolysis  and  significantly 
up-regulated this pathway when their respiration was 
inhibited [73]. The LDHA is an important member in 
Glycolysis/Gluconeogenesis  pathway.  It  could  con-
vert pyruvate, the product of glycolysis, into lactate 
and  created  an  acidic  environment  to  promote  the 
invasion of cancer cells [74]. 
Integrin-mediated  cell  adhesion  pathway  was 
closely  associated  with  cell  proliferation,  mainte-
nance, mobility and metastasis [51]. The overexpres-
sion  of  ITGAV  had  been  found  in  several  types  of 
tumors  to    be  related  to  metastasis  and  late-stage 
[34,35].  In  Koukoulis  et  al.‟s  immunohistochemistry 
assay, the LADs obtained the most strong staining for 
ITGAV,  while  the  carcinoids  and  bronchoalveolar 
carcinoma  (BAC),  a  subtype  of  LAD  which  has  no 
stromal, vascular, or pleural invasion, showed weak 
staining[75,76].  In  addition,  FYN,  a  member  of  Src 
family kinases, played an important role as a mediator 
of metastatic progression of disease apart from local 
tumor  growth  [77].  There  were  hardly  any  experi-
ments  had  been  carried  out  on  lung  cancer  about 
FYN. 
The difference between stage IA and stage IB in 
TNM staging was only the tumor size. Our pathway 
analysis  showed  that  Oxidative  stress,  Glycoly-
sis/Gluconeogenesis  and  Integrin-mediated  cell  ad-
hesion  pathways  were  SPRs  in  stage  IB  but  not  in 
stage  IA.  Genes  and  pathways  conferring  more  ag-
gressive proliferation and invasive character might be 
activated in the preinvasive stages, such as stage IB. 
The significance of the finding was that the character 
of stage IB was toward to advanced stages, the early 
stage of LAD might be stage IA only.  
The lung adjuvant cisplatin-based chemotherapy 
might  be  effective  to  stage  IB  and  more  advanced 
stages but not stage IA [12]. Cisplatin is believed to 
form  adducts  with  DNA,  inhibiting  replication  and 
transcription  [78].  However,  several  recent  studies 
have shown that the cytotoxicity of cisplatin may also 
be related to the cellular defense systems that protect 
against oxidative stress induced by hydroperoxides in 
cancer  cells.  Simons  et  al.  demonstrated  that 
2-Deoxy-D-Glucose (2DG), an agent for glucose dep-
rivation, combined with cisplatin enhances cytotoxi-
city via metabolic oxidative stress in human head and 
neck  cancer  cells  [79].  The  agent  also  increased  the 
efficacy of Adriamycin and paclitaxel in human oste-
osarcoma and NSCLC in vivo, according to Maschek 
et al.‟s assay [80]. 
The  products  of  glucose  metabolism,  pyruvate 
(from glycolysis) and NADPH (from the pentose cy-
cle), are believed to play a role in hydroperoxide de-
toxification[81,82].  So,  the  up-regulation  in  glucose 
metabolism in cancer cells might also be necessary to 
produce  more  pyruvate  to  compensate  for  the  in-
creased hydroperoxides. The insignificance of Oxida-
tive  stress  and  the  Glycolysis/Gluconeogenesis 
pathways in stage IA might explain the less benefit 
with adjuvant chemotherapy. Our pathway analysis 
result suggested strong connections between Oxida-
tive stress and cisplatin-based adjuvant chemothera-
py, as well as the Glycolysis/Gluconeogenesis path-
ways. 
These  three  pathways  revealed  the  potential 
molecular  mechanisms  differences  among  different 
stages. Moreover, comparing the stage IA and stage 
IB, stage IB had more favorable mechanism to have 
node involvement potential. It emphasized again the 
importance of tumor size in TNM staging. The insig-
nificant three pathways in stage IA might be used in 
early stage detection of LAD. Whether the genes in 
these  three  pathways  might  be  used  for  prognosis 
signature need further investigation. 
We noticed that some DEGs were found in the 
comparison of Normal vs IA and IB, but not found in 
the comparison of Normal vs IIIA and IIIB. However, 
DEGs in the comparison of Normal vs IIIA and IIIB 
were often showed in the comparison of Normal vs IA 
and IB, which indicated that mechanism of progres-
sion to stage III is different from that to stage I. We did 
not compare the data in stage II due to it is interim 
stage and few datasets (2 datasets) were involved in 
the meta-analysis.  
We  randomly  selected  18  genes  to  verify  the 
meta-analysis result  with  real-time PCR using LAD 
cell line Calu-3 and H1299 to mimic the human lung 
LAD with and without metastasis. Two genes showed 
opposite  regulation  tendency  in  the  real-time  PCR 
compared with the meta-analysis result. In the group Int. J. Biol. Sci. 2011, 7 
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A,  NT5E  had  a  fold  change  of  1.19,  and  the 
up-regulation Q value was 0.0000084866 which was 
only found in the comparison of Normal vs IB; in the 
group B, SPP1 was significantly down-regulation in 
real-time  PCR  instead  of  up-regulation  in  the  me-
ta-analysis. The other three genes, LIMK1, VIM and 
HMGA1 were in the same expression tendencies in the 
two  analyses,  but  showed  no  significant  expression 
change in real time PCR.  
Number of DEGs was dependent on the sample 
size and the number of datasets combined. When an 
individual  comparison  included  more  datasets,  the 
small sample size of some datasets might not affect 
the final result if DEGs were integrated from different 
combinations. However, when few datasets were in-
cluded, the impact of the small sample size on DEGs 
might be obvious, such as the comparison Normal vs 
IIA. It might also be the main reason why the com-
parison  between  normal  and  stage  IV  revealed  no 
DEGs.  The  comparison  could  be  made  in  only  one 
combination (Dataset2 and Dataset4), and the samples 
of stage IV were both fewer in these datasets. Further 
analysis should be taken, when more eligible datasets 
for stage IV are available. 
Conclusion 
We  identified  a  group  of  genes,  which  might 
associate with the complicated metastasis process in 
LAD using meta-analysis of different microarray da-
tasets. These genes involved in wider pathways dif-
ferences among different LAD stages. Among them, 
the adipogenesis pathway had not been reported to be 
a SRP in LAD, while the involvement of ID pathway 
in NSCLC was only reported in the last two years. 
Most of the genes from the same gene family were 
found  to  be  up-regulated  (or  down-regulated).  The 
similar  trend  of  expression  of  these  gene  family 
members  suggested  coordinate  regulation.  Im-
portantly,  meta-analysis  lead  to  fewer  DEGs  and 
produced higher probability of false negatives when 
integrating  datasets  with  smaller  sample  size.  Cau-
tions should be taken when interpreted the result of 
meta-analysis  with small sample size involved. The 
insignificant  three  pathways  (Oxidative  stress,  Gly-
colysis/Gluconeogenesis  and  Integrin-mediated  cell 
adhesion  pathways)  in  stage  IA  might  be  used  in 
early-stage detection of LAD.  
Supplementary Material 
Additional File 1:  
Supplementary Table 1: The expression of 1 838 DEGs in 
the six different comparisons.  
Supplementary Table 2: All pathways derived from the 
six comparisons and its corresponding Z scores.  
Supplementary Table 3: All GOs derived from the six 
comparisons and its corresponding Z scores.  
http://www.biolsci.org/v07p0551s1.pdf 
Additional File 2:  
Supplementary Figure 1: The Q values of stage IA from all 
two datasets combinations for 9 genes in group A.    
http://www.biolsci.org/v07p0551s2.pdf 
Acknowledgments 
We would like to thank the contributors for re-
leasing  the  microarray  datasets.  We  also  appreciate 
Fenghua Guo‟s work on Perl program. This research 
was supported by National Natural Science Founda-
tion of China grant 31071223 and Ministry of Educa-
tion of China grant 20070246153. 
Authors' contributions 
CC participated in the design of the study, per-
formed the statistical analysis and drafted the manu-
script. XF participated in the statistical analysis and 
helped to draft the manuscript. DZ and YL (Yuan Li) 
participated  in  cancer  cells  culture  and  carried  out 
real-time PCR assay. YX participated in the statistical 
analysis. YL (Yao Li) organized all the research and 
provided  advice  for  preparing  the  manuscript.  YH 
conceived  of  the  study,  organized  all  the  research, 
participated in its design and coordination and helped 
to  revise  the  manuscript.  All  authors  read  and  ap-
proved the final manuscript. 
Conflict of Interests 
The authors have declared that no conflict of in-
terest exists. 
References 
1.   Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, et al. Annual 
report to the nation on the status of cancer, 1975-2005, featuring 
trends in lung cancer, tobacco use, and tobacco control. J Natl 
Cancer Inst. 2008; 100: 1672-1694. 
2.  Kopfstein  L,  Christofori  G.  Metastasis:  cell-autonomous 
mechanisms  versus  contributions  by  the  tumor 
microenvironment. Cell Mol Life Sci. 2006; 63: 449-468. 
3.   Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. Oncogenic 
pathway signatures in human cancers as a guide to targeted 
therapies. Nature. 2005; 439: 353-357. 
4.   Mareel M, Leroy A. Clinical, cellular, and molecular aspects of 
cancer invasion. Physiol Rev. 2003; 83: 337-376. 
5.   Nordquist  LT,  Simon  GR, Cantor  A,  Alberts WM, Bepler G. 
Improved survival in never-smokers vs current smokers with 
primary adenocarcinoma of the lung. Chest. 2004; 126: 347-351. 
6.   Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, et al. 
Bronchioloalveolar  carcinoma  and  lung  adenocarcinoma:  the 
clinical importance and research relevance of the 2004 World 
Health  Organization  pathologic  criteria.  Journal  of  Thoracic 
Oncology. 2006; 1: S13. 
7.   Travis  WD,  Brambilla  E,  Muller-Hermelink  HK,  Harris  CC. 
Pathology and genetics of tumours of the lung, pleura, thymus 
and heart. Lyon: Iarc. 2004 Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
565 
8.   Kratz  JR,  Jablons  DM.  Genomic  Prognostic  Models  in 
Early-Stage  Lung  Cancer.  Clinical  Lung  Cancer.  2009;  10: 
151-157. 
9.   Rami-Porta  R,  Crowley  JJ,  Goldstraw  P.  The  revised  TNM 
staging system for lung cancer. Ann Thorac Cardiovasc Surg. 
2009; 15: 4-9. 
10.  Spira  A,  Ettinger  DS.  Multidisciplinary  management  of  lung 
cancer. New England Journal of Medicine. 2004; 350: 379. 
11.  Booth CM, Shepherd FA. Adjuvant chemotherapy for resected 
non-small cell lung cancer. Journal of Thoracic Oncology. 2006; 
1: 180. 
12.  Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, et al. The 
present  status  of  postoperative  adjuvant  chemotherapy  for 
completely  resected  non-small  cell  lung  cancer.  Annals  of 
Thoracic and Cardiovascular Surgery. 2007; 13: 73. 
13.  Kato  H,  Ichinose  Y,  Ohta  M,  Hata  E,  Tsubota  N,  et  al.  A 
randomized trial of adjuvant chemotherapy with uracil-tegafur 
for adenocarcinoma of the lung. The New England journal of 
medicine. 2004; 350: 1713. 
14.  Ramaswamy  S,  Golub  TR.  DNA  microarrays  in  clinical 
oncology. Journal of Clinical Oncology. 2002; 20: 1932. 
15.  Chen  HY,  Yu  SL,  Chen  CH,  Chang  GC,  Chen  CY,  et  al.  A 
five-gene signature and clinical outcome in non-small-cell lung 
cancer. The New England journal of medicine. 2007; 356: 11. 
16. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, et al. 
Survival  prediction  of  stage  I  lung  adenocarcinomas  by 
expression of 10 genes. J Clin Invest. 2007; 117: 3436-3444. 
17.  Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, et al. 
Three-gene prognostic classifier for early-stage non small-cell 
lung cancer. Journal of Clinical Oncology. 2007; 25: 5562. 
18.  Alizadeh  AA,  Eisen  MB,  Davis  RE,  Ma  C,  Lossos  IS,  et  al. 
Distinct types of diffuse large B-cell lymphoma identified by 
gene expression profiling. Nature. 2000; 403: 503-511. 
19.  Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays 
for cancer outcomes and correlates: an empirical assessment. 
Lancet. 2003; 362: 1439-1444. 
20.  Jafari P, Azuaje F. An assessment of recently published gene 
expression data analyses:  reporting  experimental design and 
statistical factors. BMC Med Inform Decis Mak. 2006; 6: 27. 
21.  Warnat  P,  Eils  R,  Brors  B.  Cross-platform  analysis  of  cancer 
microarray data improves gene expression based classification 
of phenotypes. BMC Bioinformatics. 2005; 6: 265. 
22.  Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues 
in conducting a meta-analysis of gene expression microarray 
datasets. PLoS Med. 2008; 5: e184. 
23. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling 
pathways:  roadmap  for  therapies.  European  Respiratory 
Journal. 2009; 33: 1485. 
24.  Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. 
Meta-analysis  of  microarrays:  interstudy  validation  of  gene 
expression profiles reveals pathway dysregulation in prostate 
cancer. Cancer Res. 2002; 62: 4427-4433. 
25.  Adams  MD,  Soares  MB,  Kerlavage  AR,  Fields  C,  Venter  JC. 
Rapid  cDNA  sequencing  (expressed  sequence  tags)  from  a 
directionally  cloned  human  infant  brain  cDNA  library.  Nat 
Genet. 1993; 4: 373-380. 
26.  Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: 
A Practical and Powerful Approach to Multiple Testing. Journal 
of the Royal Statistical Society, Series B (Methodological). 1995; 
57(1): 289-300. 
27.  Livak KJ, Schmittgen TD. Analysis of relative gene expression 
data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods. 2001; 25: 402-408. 
28.  Luo Y, Liang F, Zhang ZY. PRL1 Promotes Cell Migration and 
Invasion by Increasing MMP2 and MMP9 Expression through 
Src  and  ERK1/2  Pathways  (dagger).  Biochemistry.  2009;  48: 
1838-1846. 
29.  Cheng CY, Hsieh HL, Sun CC, Lin CC, Luo SF, et al. IL-1 beta 
induces  urokinase-plasminogen  activator  expression  and  cell 
migration  through  PKC  alpha,  JNK1/2,  and  NF-kappaB  in 
A549 cells. J Cell Physiol. 2009; 219: 183-193. 
30. Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, et al. 
ERBB1  and  ERBB2  Have  Distinct  Functions  in  Tumor  Cell 
Invasion  and  Intravasation.  Clin  Cancer  Res.  2009;  15: 
3733-3739. 
31.  Malinowski  DP.  Minichromosome  Maintenance  (MCM) 
Proteins as Tumor Markers: The Detection of MCM Proteins as 
Markers  of  Aberrant  S-Phase  Entry  in  Cervical  Neoplasia. 
Tumor Markers Research Focus. 2007;: 47. 
32.  S  owiński  J,  Mazurek  U,  Bierzyńska-Macyszyn  G.  Histone 
mRNA in situ hybridization in assessing proliferative activity 
of  normal  and  malignant  cells.  Folia  histochemica  et 
cytobiologica/Polish  Academy  of  Sciences,  Polish 
Histochemical and Cytochemical Society. 2002; 40: 335. 
33.  Orchel J, Slowinski J, Mazurek U, Wilczok T. H3 mRNA level as 
a  new  proliferative  marker  in  astrocytomas.  BBA-Molecular 
Basis of Disease. 2004; 1689: 42-46. 
34.  Lu JG, Sun YN, Wang C, Jin DJ, Liu M. Role of the αv-integrin 
subunit in cell proliferation, apoptosis and tumor metastasis of 
laryngeal  and  hypopharyngeal  squamous  cell  carcinomas:  a 
clinical  and  in  vitro  investigation.  European  Archives  of 
Oto-Rhino-Laryngology. 2009; 266: 89-96. 
35.  Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, et al. 
{alpha} v {beta} 6 Integrin Promotes the Invasion of Morphoeic 
Basal  Cell  Carcinoma  through  Stromal  Modulation.  Cancer 
research. 2008; 68: 3295. 
36.  Giancotti  FG.  Targeting  integrin  β4  for  cancer  and 
anti-angiogenic therapy.  Trends in  Pharmacological  Sciences. 
2007; 28: 506-511. 
37. Nakano KY, Iyama KI, Mori T, Yoshioka M, Hiraoka T, et al. 
Loss of alveolar basement membrane type IV collagen 3, 4, and 
5 chains in bronchioloalveolar carcinoma of the lung. J Pathol. 
2001; 194: 420-427. 
38.  Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, et al. Snail 
and SIP1 increase cancer invasion by upregulating MMP family 
in hepatocellular carcinoma cells. British journal of cancer. 2004; 
90: 1265. 
39.  Trayhurn  P,  Wood  IS.  Adipokines:  inflammation  and  the 
pleiotropic  role  of  white  adipose  tissue.  Br  J  Nutr.  2004;  92: 
347-355. 
40.  Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, et al. Disturbance 
of circadian gene expression in breast cancer. Virchows Arch. 
2009; 454: 467-474. 
41.  Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, et al. 
Correlated downregulation of estrogen receptor beta and the 
circadian  clock  gene  Per1  in  human  colorectal  cancer.  Mol 
Carcinog. 2009; 48: 642-647. 
42.  Pogue-Geile  KL,  Lyons-Weiler  J,  Whitcomb  DC.  Molecular 
overlap of fly circadian rhythms and human pancreatic cancer. 
Cancer Lett. 2006; 243: 55-57. 
43.  Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, et al. Abnormal 
expression  of  period  1  (PER1)  in  endometrial  carcinoma.  J 
Pathol. 2005; 206: 111-120. 
44.  Lin  YM,  Chang  JH,  Yeh  KT,  Yang  MY,  Liu  TC,  et  al. 
Disturbance  of  circadian  gene  expression  in  hepatocellular 
carcinoma. Mol Carcinog. 2008; 47: 925-933. 
45.  Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of 
development and cancer. Oncogene. 2001; 20: 8326-8333. 
46. Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman 
J, et al. Identification of importin 8 (IPO8) as the most accurate 
reference  gene  for  the  clinicopathological  analysis  of  lung 
specimens. BMC Mol Biol. 2008; 9: 103. Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
566 
47.  Morimoto I, Sasaki Y, Ishida S, Imai K, Tokino T. Identification 
of  the  osteopontin  gene  as  a  direct  target  of  TP53.  Genes 
Chromosomes Cancer. 2002; 33: 270-278. 
48. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative 
stress in cancer. FEBS Lett. 1995; 358: 1-3. 
49.  Franco  R,  Schoneveld  O,  Georgakilas  AG,  Panayiotidis  MI. 
Oxidative stress, DNA methylation and carcinogenesis. Cancer 
Lett. 2008; 266: 6-11. 
50.  Moreno-Sanchez  R,  Rodriguez-Enriquez  S,  Saavedra  E, 
Marin-Hernandez A, Gallardo-Perez JC. The bioenergetics of 
cancer: Is glycolysis the main ATP supplier in all tumor cells? 
Biofactors. 2009; 35: 209-225. 
51.  Chen X, Sievers E, Hou Y, Park R, Tohme M, et al. Integrin 
alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005; 
7: 271-279. 
52.  Vogelstein B, Kinzler KW. Cancer genes and the pathways they 
control. Nat Med. 2004; 10: 789-799. 
53.  Carelli  S,  Zadra  G,  Vaira  V,  Falleni  M,  Bottiglieri  L,  et  al. 
Up-regulation of focal adhesion kinase in non-small cell lung 
cancer. Lung Cancer. 2006; 53: 263-271. 
54.  Hirano T, Morii H, Nakazawa K, Murakami D, Yamashita A, et 
al.  Enhancement  of  adipogenesis  induction  by  conditioned 
media  obtained  from  cancer  cells.  Cancer  Lett.  2008;  268: 
286-294. 
55.  Motrescu  ER,  Rio  MC.  Cancer  cells,  adipocytes  and  matrix 
metalloproteinase 11: a vicious tumor progression cycle. Biol 
Chem. 2008; 389: 1037-1041. 
56.  Bouloumie A, Sengenes C, Portolan G, Galitzky J, Lafontan M. 
Adipocyte  produces  matrix  metalloproteinases  2  and  9: 
involvement  in  adipose  differentiation.  Diabetes.  2001;  50: 
2080-2086. 
57.  Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, et al. 
Epigenetic silencing of the candidate tumor suppressor gene 
Per1 in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 
1399-1404. 
58.  Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, et al. 
Increased expression of Id family proteins in small cell lung 
cancer and its prognostic significance. Clin Cancer Res. 2008; 14: 
2318-2325. 
59.  Rollin J, Blechet C, Regina S, Tenenhaus A, Guyetant S, et al. 
The intracellular localization of ID2 expression has a predictive 
value in non small cell lung cancer. PLoS ONE. 2009; 4: e4158. 
60.  Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams 
AC,  et  al.  The  COX-2/PGE2  pathway:  key  roles  in  the 
hallmarks  of  cancer  and  adaptation  to  the  tumour 
microenvironment. Carcinogenesis. 2009; 30: 377-386. 
61.  Murata T, Lin MI, Aritake K, Matsumoto S, Narumiya S, et al. 
Role of prostaglandin D2 receptor DP as a suppressor of tumor 
hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci 
U S A. 2008; 105: 20009-20014. 
62.  Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S. Prostaglandin 
E2  stimulates  human  lung  carcinoma  cell  growth  through 
induction of integrin-linked kinase: the involvement of EP4 and 
Sp1. Cancer Res. 2009; 69: 896-904. 
63. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, et 
al. Statin use and breast cancer risk in a large population-based 
setting. Cancer Epidemiol Biomarkers Prev. 2007; 16: 416-421. 
64. Antoine-Jonville S, Hue O. Cholesterol, statins, and mortality. 
Lancet. 2008; 371: 1163. 
65. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, 
et al. Statin use and breast cancer: prospective results from the 
Women's Health Initiative. J Natl Cancer Inst. 2006; 98: 700-707. 
66. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A 
systematic review and meta-analysis. Eur J Cancer. 2008; 44: 
2122-2132. 
67.  Mori  K,  Shibanuma  M,  Nose  K.  Invasive  potential  induced 
under long-term oxidative stress in mammary epithelial cells. 
Cancer Res. 2004; 64: 7464-7472. 
68.  Svensk  AM,  Soini  Y,  Paakko  P,  Hirvikoski  P,  Kinnula  VL. 
Differential  expression  of  superoxide  dismutases  in  lung 
cancer.  American  journal  of  clinical  pathology.  2004;  122: 
395-404. 
69.  Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, et al. Alteration of 
APE1/ref-1  expression  in  non-small  cell  lung  cancer:  The 
implications  of  impaired  extracellular  superoxide  dismutase 
and  catalase  antioxidant  systems.  Lung  cancer.  2008;  60: 
277-284. 
70.  Trachootham D, Alexandre J, Huang P. Targeting cancer cells 
by ROS-mediated mechanisms: a radical therapeutic approach? 
Nature Reviews Drug Discovery. 2009; 8: 579-591. 
71.  Ray S, Watkins DN, Misso NLA, Thompson PJ. Oxidant stress 
induces  gamma-glutamylcysteine  synthetase  and  glutathione 
synthesis  in  human  bronchial  epithelial  NCI-H292  cells. 
Clinical & Experimental Allergy. 2002; 32: 571-577. 
72.  Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect 
and mitochondrial stability in cancer cells. Molecular aspects of 
medicine. 2009; 31: 60-74. 
73.  Wu  M,  Neilson  A,  Swift  AL,  Moran  R,  Tamagnine  J,  et  al. 
Multiparameter metabolic analysis reveals a close link between 
attenuated mitochondrial bioenergetic function and enhanced 
glycolysis dependency in human tumor cells. American Journal 
of Physiology- Cell Physiology. 2007; 292: C125. 
74.  Gillies  RJ,  Gatenby  RA.  Adaptive  landscapes  and  emergent 
phenotypes: why do cancers have high glycolysis? Journal of 
Bioenergetics and Biomembranes. 2007; 39: 251-257. 
75.  Koukoulis  GK,  Warren  WH,  Virtanen  I,  Gould  VE. 
Immunolocalization  of  integrins  in  the  normal  lung  and  in 
pulmonary carcinomas. Human pathology. 1997; 28: 1018-1025. 
76.  Arenberg D. Bronchioloalveolar Lung Cancer*. Chest. 2007; 132: 
306S. 
77.  Saito  YD,  Jensen  AR,  Salgia  R,  Posadas  EM.  Fyn:  a  novel 
molecular target in cancer. Cancer. 2010; 116: 1629-1637. 
78.  Germain  CS,  Niknejad  N,  Ma  L,  Garbuio  K,  Hai  T,  et  al. 
Cisplatin Induces Cytotoxicity through the Mitogen-Activated 
Protein Kinase Pathways and Activating Transcription Factor 3. 
Neoplasia. 2010; 12: 527-538. 
79.  Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 
2-Deoxy-D-glucose  combined  with  cisplatin  enhances 
cytotoxicity via metabolic oxidative stress in human head and 
neck cancer cells. Cancer research. 2007; 67: 3364. 
80. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton 
K, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin 
and paclitaxel in human osteosarcoma and non-small cell lung 
cancers in vivo. Cancer research. 2004; 64: 31. 
81. Tuttle SW, Varnes ME, Mitchell JB, Biaglow JE. Sensitivity to 
chemical oxidants and radiation in CHO cell lines deficient in 
oxidative  pentose  cycle  activity.  International  Journal  of 
Radiation Oncology* Biology* Physics. 1992; 22: 671-675. 
82.  Averillbates  DA,  Przybytkowski  E.  The  role  of  glucose  in 
cellular defenses against cytotoxicity of hydrogen peroxide in 
Chinese  hamster  ovary  cells.  Archives  of  biochemistry  and 
biophysics. 1994; 312: 52-58. 